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Abstract Medical device related infections caused by
coagulase-negative staphylococci (CoNS) are difficult to
treat mainly because of the increased bacterial genetic tol-
erance to antibiotics and its notorious biofilm formation
property which has been reported to be achieved through
a wide range of mechanisms. Current study is the demon-
stration of persistent antibiotic delivering potential and
broad spectrum of activity of nanoantibiotic combinations
designed from gold nanoparticles in conjugation with
known antimicrobial agents. Such formulations are of
potential applications as surface engineering agents on
medical devices to prevent device mediated infection
caused by pathogens like CoNS. For this, highly stable
gold nanoparticles fabricated by a Bacillus sp. were
functionalized with ciprofloxacin, gentamycin, rifampi-
cin, and vancomycin and these nanoparticle-antibiotic
conjugates were studied for its effectiveness against
selected CoNS like Staphylococcus epidermidis and
Staphylococcus haemolyticus. Very interestingly, the de-
signed conjugates were identified to have a profound
antibacterial efficiency compared to pure antibiotic and
AuNPs. Thus, the result of the study is with highly
significant medical applications as the test organisms
used are emerging opportunistic pathogens.
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Introduction
Microbial development of resistance mechanisms and escala-
tion of emerging and re-emerging infectious diseases associat-
ed with medical procedures have become a serious problem
with great concern to public health [1]. This demands design
of new antimicrobial drugs with highly efficient and improved
delivery potential by utilization of knowledge from recent ad-
vances in nanomaterial research [2]. The unique physical prop-
erties of nanoscale materials have shown to have promises to
develop wide array methods for cost-effective diagnosis, rapid
determination of resistance of antibacterial drugs, and efficient
delivery of antimicrobial agents [3]. Their application as drug
delivery vehicles is due to its advantages such as controlled
release, improved solubility, specific site-targeted delivery,
minimized side effects, and enhanced cellular internalization.
Additional advantages of nanoantimicrobial formulations in-
cluding its protective effect toward antimicrobial drugs and
ability to overcome resistance in conjugation with antibiotics
[4–6]. This demands studies on exploration of antimicrobial
nanomaterials and novel nanosized platforms for clinical
applications.
Nanoparticles can act as mediators of drug release, and
thus, they have been used to enhance the selectivity and effi-
ciency of the drug delivery system. In addition, because of
their extremely small size and high surface area, their surfaces
can be modified with hydrophobic, hydrophilic, cationic, an-
ionic, or any neutral moieties and can easily travel into the
target cells and allow high drug load. Various nanoparticles
have been investigated as efficient delivery vehicles for the
effective administration of wide range of antimicrobial agents.
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They are also suggested to protect antimicrobial drugs from
resistant mechanisms in target microbes. Also, many types of
lipophilic and water-soluble antibiotics have been reported to
be conjugated inside or on the surface of nanoparticles, or
carried via encapsulation [7]. Among all metal nanoparticles,
gold nanoparticles (AuNPs) have been considered to be highly
useful platform for the efficient drug delivery/carrier system
due to their facile and well-studied synthesis, easy surface
functionalization and biocompatibility and less toxicity [8].
Also, AuNPs have shown to increase drug concentration at
infected site with reduced toxicity of the drug [9]. This make
gold nanoparticles to be used as therapeutic agents or vaccine
carriers in to specific cells to increase the efficiency of antibi-
otics therapy in treating serious bacterial infections at a re-
duced antibiotics dosage with minimal adverse effects.
Gold nanoparticle conjugates were reported to have prom-
ising applications against both gram-positive and gram-
negative bacteria and also against those where the biofilm for-
mation forms the basis of infection. Vancomycin-bound bio-
genic gold nanoparticles (VBGNP) have shown to have excel-
lent antibacterial activity against resistant Staphylococcus
aureus and Escherichia coli compared to their free forms
[10]. Also, vancomycin-capped AuNPs were demonstrated to
have enhanced antibacterial activity against vancomycin-
resistant enterococci (VRE) [11]. In addition to this, AuNPs
functionalized with ampicillin were found to have effective
action as broad spectrum bactericides against wide range of
bacteria [12]. Gold nanoparticles have also been exploited for
its function as carrier for antibiotics such as streptomycin, neo-
mycin, gentamycin, kanamycin [13–16], and fluorouracil [17].
These studies indicate the promising applications of AuNPs,
and hence, it is of particular interest to design AuNP-based
conjugates to engineer surface of medical devices to efficiently
prevent organisms like CoNS which cause infections associat-
ed with insertion of medical devices.
CoNS are highly specialized organisms for the diversity in
mechanisms for biofilm formation which make them to escape
easily from the action of antimicrobial drugs. As biofilm-
forming microorganisms are notoriously resistant to antimi-
crobial agents, their treatment is very difficult and biofilm
formation on surfaces of medical implants is very problematic.
Thus, in the current work, biogenic AuNPs functionalized
with antibiotics were studied for its effectiveness against
multidrug-resistant and biofilm-forming coagulase-negative
staphylococcal (CoNS) strains isolated from clinical samples.
Gold nanoparticles fabricated by the selectedBacillus sp. were
characterized by UV–Vis spectroscopy, FTIR, HR-TEM, and
EDS. Very interestingly, biosynthesized AuNPs when conju-
gated with ciprofloxacin, gentamycin, rifampicin, and vanco-
mycin were found to have reduced minimum inhibitory con-
centration (MIC) when compared to their unconjugated free
forms against tested CoNS which adds novelty and signifi-
cance of the study.
Experimental details
Biosynthesis and purification of gold nanoparticles
Bacillus sp. (SJ 14) isolated and characterized for silver
nanoparticle (AgNPs) synthesizing property in our previ-
ous study [18] was also selected as source organism for
the synthesis of gold nanoparticles using aqueous solution
of gold(III) chloride hydrate (HAuCl4; Sigma-Aldrich).
Bacterial biomass was grown in a specially prepared
liquid culture medium (0.5 % peptone, 0.15 % beef ex-
tract, 0.15 % yeast extract, and 1 % NaCl, pH 7). The
inoculated broth was maintained at room temperature un-
der constant agitation at 200 rpm in a rotating shaker for
24 h. After incubation, the biomass was collected by cen-
trifugation at 10,000 rpm for 10 min and washed thor-
oughly with sterile deionized water to remove any adher-
ing media components. About 2 g of bacterial wet bio-
mass was resuspended in 100-mL aqueous solution of
filter-sterilized 1 mM HAuCl4 in a 250-mL Erlenmeyer
flask for the synthesis of gold nanoparticles. The bacterial
biomass incubated without chloroauric acid (HAuCl4)
was maintained as control. After synthesis, the whole
bacterial mixture with AuNPs was centrifuged at 15,
000 rpm for 15 min, and the collected pellets were
washed and resuspended in 50 mM Tris buffer (pH 7).
The cells were disrupted by ultrasonication over three
15-s periods and with an interval of 45 s between
periods (Sonics-Vibra Cell). The resulting solution was
then filtered through a 0.22-μm filter (Millipore), and
the purified AuNPs thus obtained was used for further
characterization.
Characterization of gold nanoparticles
The formation of gold nanoparticles was indicated by a
visual color change from light yellow to dark purple. The
bioreduction of the AuCl4− ions in solution was moni-
tored by measuring the UV–Vis spectra of the reaction
mixture using Hitachi U5100 spectrophotometer in the
range of 400–800 nm at a resolution of 1 nm. The purified
AuNPs were also characterized by Fourier transform in-
frared (FTIR) spectrometer to identify the possible bio-
molecules at a resolution of 4 cm−1 in the range of
4000–450 cm−1 (Schimadzu IR Prestige 21). High-
resolution transmission electron microscopy (HR-TEM)
and selected area electron diffraction (SAED) studies
were prepared by drop coating of Au nanoparticles onto
carbon-coated copper grids (JEOL-TEM) to confirm the
microstructure of the nanoparticles. The surface inter-
atomic distribution of AuNPs was also analyzed using
energy-dispersive spectroscopy (EDS).
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Antibacterial activity of gold nanoparticles
Antibacterial activity of AuNPs was evaluated against multi-
drug-resistant, biofilm-forming coagulase-negative
Staphylococcus epidermidis (sample ID 73,152, 78) and
Staphylococcus haemolyticus (sample ID 41) strains isolated
from clinical samples obtained from the MOSC Medical
College, Kolencherry, Kerala, India [18]. The inoculum of
each bacterium was developed by growing the CoNS strains
in trypticase soy broth (TSB) at 37 °C for 18–24 h. The tur-
bidity of the culture was maintained by comparing with 0.5
McFarland Standard by diluting with 0.9 % NaCl solution.
Wells of 6 mm were made on the Muller-Hinton agar
(MHA) plates using a gel puncture, and the plates were inoc-
ulated by swabbing the bacterial pathogens to create a conflu-
ent lawn of bacterial growth. Wells were then filled with 20 μl
of biosynthesized AuNPs (20 μg/ml). HAuCl4 solution
(1 mM) and bacterial supernatant obtained after
ultrasonication of biomass were poured on to respective wells
as negative control, and plates were incubated at 37 °C for
24 h. The formation of clear zone around the wells is taken as
an indication of antibacterial activity. The experiment was
performed in triplicate.
Disk diffusion assay to evaluate the combined effects
of AuNPs and antibiotics
The antibacterial potential of antibiotics in the presence of
biosynthesized AuNPs was assessed by standard disk diffu-
sion method against CoNS strains on MHA plates [19]. The
standard antibiotic disks (gentamycin 30 μg/disk, ciprofloxa-
cin 30 μg/disk, nalidixic acid 30 μg/disk, methicillin 5 μg/
disk, rifampicin 15 μg/disk, and vancomycin 30 μg/disk)
were purchased from Himedia (Mumbai, India). The inocula
were prepared by diluting the overnight cultures of bacterial
pathogens in TSB with 0.9 % NaCl to a 0.5 McFarland stan-
dard and were swabbed uniformly onto the individual MHA
plates using sterile cotton swabs. Then, AuNPs impregnated
air-dried antibiotic disks (20 μl of freshly prepared AuNPs
with the final content of 20 μg of AuNPs per disk) and anti-
biotic disk alone as control were placed aseptically on the
surface of the plates. Plates were incubated at 37 °C for 24 h
to check the antibacterial activity and were expressed as zone
of inhibition in millimeter around each disk. The fold increase
area of different antibiotics against CoNS strains was calcu-
lated by the equation (b2−a2) / a2, where a and b are zone of
inhibitions for antibiotic and antibiotic plus AgNPs, respec-
tively. The assays were implemented in triplicate.
Functionalization biogenic AuNPs with antibiotics
For this, stock solution (1 mg/ml) of ciprofloxacin,
gentamycin, rifampicin, and vancomycin hydrochloride
(Himedia, Mumbai, India) were prepared. Further,
antibiotics-bound biogenic gold nanoparticles were prepared
by stirring 1 ml of antibiotic solution with equal volume of
biosynthesized AuNPs (20 μg/ml) for 15 min, followed by
incubation for overnight at room temperature. The resulting
functionalized nanoparticles were centrifuged, and the pellet
was resuspended in sterile deionized water and stored in the
dark at 4 °C [10, 12]. The formations of antibiotic-AuNP
conjugates were characterized using UV–Vis spectroscopy
(Hitachi U5100 spectrophotometer) in the range of 300–
800 nm and FTIR (Schimadzu IR Prestige 21) in the range
of 4000–450 cm−1.
Analysis of MIC of free and AuNP-conjugated antibiotics
The MIC of biogenic gold nanoparticles functionalized with
antibiotics against CoNS strains (S. epidermidis 73,152, 78
and S.haemolyticus 41) were conducted by standard
microbroth dilution method according to the guidelines of
the Clinical Laboratory Standards Institute (CLSI) using 96-
well microtiter plates (Thermo Scientific Varioskan Flash
multimode reader).
The CoNS strains were inoculated into TSB and incubated
at 37 °C. The overnight cultures of CoNSwere diluted by TSB
to a 0.5 McFarland standard with bacterial cell density around
108 CFU/ml. Subsequently, the cultures were added to two-
fold dilutions of antibiotics and AuNP-conjugated antibiotics
in concentrations ranging from 500 to 0.976 μg/ml. Growth
and sterility control wells were maintained in each microtiter
plate, and the plates were incubated at 37 °C for 24 h. The
assays were performed in triplicate to confirm the value of
MIC of both free and AuNP-bound antibiotics for each tested
bacteria. The MIC endpoint was considered as the lowest
concentration at which there is no visible growth in the wells
[10].
Results and discussion
CoNS species including the well-documented S. epidermidis
are the major cause of device-associated infections. Other
CoNS species such as S. haemolyticus are also extensively
associated with implantation failure. The success in the colo-
nization and development of CoNS infection has been related
to the capacity of these organisms to produce biofilm. Once
biofilm formation occurs onmedical devices, dissemination of
cells from this to other parts of the body happens which result
in CoNS infection. Added challenge to this is the emerging
resistance among these microorganisms toward traditional an-
tibacterial treatments. So, alternative strategies to control
CoNS infections by exploring the unique features of nanopar-
ticles are highly attractive for these biofilm-mediated, drug-
resistant, and device-centered infections. By engineering
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surface of medical devices with NP-antibiotic conjugates, the
early steps in bacterial infection can be prevented which offer
much clinical applications.
Synthesis and characterization of AuNPs
Bacillus sp. SJ 14 (KJ451478) isolated previously from soil of
jewelry premises were used for the biosynthesis of gold nano-
particles. Biosynthesis of AuNPs was visually inspected by
distinct color change of reaction mixture from pale yellow to
dark purple within 6 h after treating bacterial biomass with
1 mM AuCl4 (Fig. 1a). The appearance of dark purple color
is the first evidence of the reduction of the gold ions to gold
nanoparticles and is due to the excitation of surface plasmon
resonance (SPR) of typical gold nanoparticles [20]. In addi-
tion, the intensity of color increased up to 24 h and maintained
throughout the experiment. However, no color change was
observed in the flasks containing bacterial biomass without
1 mM AuCl4.
Further UV–Vis spectroscopy analysis was used to check
the formation and stability of biosynthesized AuNPs in aque-
ous solution, because metallic nanoparticles display character-
istic optical absorption spectra in the UV–Vis region. The
spectra showed an intense peak at 540 nm (Fig. 2) correspond-
ing to the surface plasmon band of gold nanoparticles [21].
The narrow peak also revealed the formed gold nanoparticles
as monodispersed in solutions. In addition, the stability of the
gold nanoparticles were analyzed by UV–vis spectroscopy
after 1 year of storage at 4 °C. There was no change in color
of the AuNP solution and absorption peaks even after this
period, which might be taken as indication of stability of
biosynthesized gold nanoparticles. This may be due to the
capping of AuNPs with biomolecules during synthesis, which
balances the electrostatic force around them and provides sta-
bility against aggregation [22]. The role of proteins involved
in the reduction of Au ions and AuNPs formation was inves-
tigated using FTIR spectroscopy. The FTIR spectrum of the
biosynthesized gold nanoparticles showed an intense
absorption bands located in the region of 3381–3259 cm−1
and also at 1643 and 1633 cm−1 (Fig. 3). This may be assigned
to the amide bands of proteins and arises due to carbonyl
stretch and free-N–H stretch vibrations in the amide linkages
of the proteins. Thus, based on FTIR spectroscopic study, it
was confirmed that the carbonyl group of amino acid residues
and peptides of proteins have the stronger ability to bind met-
al. This evidence also suggests the possible role of proteins in
the formation and also stabilization of AuNPs by covering
around them to prevent agglomeration [23]. In addition, the
capped proteins have previously been reported to retain their
secondary structure on nanoparticle surface to make them bio-
compatible [24].
Further, the morphological analysis of the gold nanoparti-
cles was done with HR-TEM. It was found that the synthe-
sized nanoparticles were predominantly spherical in shape. In
addition, hexagonal and triangular nanoparticles were also
found and the sizes of formed AuNPs were in the range of
12–32 nm (Fig. 4a–g). The corresponding image of SAED
III
baFig. 1 a Visual observation ofthe biosynthesis of AuNPs by
Bacillus sp. after 24 h. I, bacterial
biomass with 1 mM HAuCl4
solution (color change from pale
yellow to dark purple); II,
bacterial biomass without
HAuCl4 (b) purified AuNPs
Fig. 2 UV–Vis spectra of AuNPs synthesized by Bacillus sp.
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Fig. 4 HR-TEM images
indicating the formation of
spherical, triangular, and
hexagonal gold nanoparticles at
different magnifications (a–g)
SAED pattern of AuNPs (h) EDS
spectrum of silver nanoparticles
(i)
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patterns with bright circular spots revealed the biosynthesized
gold nanoparticles as crystalline in nature (Fig. 4h). The EDS
spectrum of AuNPs showed strong signals at 1.5 keV, which
confirmed the presence of elemental gold in the sample
(Fig. 4i).
Antibacterial activity of gold nanoparticles
In the study, antibacterial activity of biosynthesized AuNPs
were performed against multidrug-resistant, biofilm-forming
coagulase-negative S. epidermidis (sample ID 73,152, 78) and
S. haemolyticus (sample ID 41) strains based on standard well
diffusion assay. There was no zone of inhibition for
biosynthesized AuNPs, which confirmed the gold nanoparti-
cles as with no adverse effect against the test strains (Online
Resource 1). AuNPs by itself have already been reported to be
nontoxic to E. coli, Vibrio cholerae, drug-resistant isolates of
MRSA, Enterobacter aerogenes, and Pseudomonas
aeruginosa, but have shown to become bactericidal in the
presence of antibiotic ampicillin [12]. Antibacterial activity
analysis of gold nanoparticles assessed against E. coli,
Shewanella oneidensis, and Bacillus subtilis also showed its
nontoxic effect toward bacteria [25].
The antibacterial efficacy of biosynthesized gold nanopar-
ticles in combination with various antibiotics was analyzed
based on disk diffusion method. Table 1 shows the diameter
of the zone of inhibition around antibiotics disk with and
without gold nanoparticles against CoNS strains. The activity
of all antibiotics except methicillin and nalidixic acid against
all the test strains were increased and highest fold increase in
area was observed in the case of vancomycin against
S. epidermidis strain 73 (Online Resource 2). The prevalence
of vancomycin resistance among clinical isolates of CoNS-
like S. epidermidis, S. haemolyticus, Staphylococcus warneri,
and Staphylococcus hominis has become a growing challenge
as presented in many studies and hence the observed the result
is highly significant [26, 27]. Because of the large surface area
to volume ratio of AuNPs, more antibiotic molecules might
have possibly adsorbed on the nanoparticle surface to act as a
single group against microorganisms [15]. Thus, the observed
Table 1 Zone of inhibition of
antibiotics in the presence and
absence of gold nanoparticles
against CoNS
CoNS Antibiotics Zone of inhibition (mm)
Antibiotics only Antibiotic + AuNPs Increase in fold area
(a) (b) (b2−a2/a2)
S.epidermidis 73 Gentamycin 26 28 0.16
Ciprofloxacin 35 37 0.12
Methicillin No zone No zone 0
Nalidixic acid 19 19 0
Rifampicin 36 40 0.23
Vancomycin 14 16 0.31
S.epidermidis 152 Gentamycin 16 18 0.27
Ciprofloxacin 25 27 0.17
Methicillin No zone No zone 0
Nalidixic acid No zone No zone 0
Rifampicin No zone No zone 0
Vancomycin 15 16 0.16
S.epidermidis 78 Gentamycin 29 30 0
Ciprofloxacin 33 36 0.19
Methicillin No zone No zone 0
Nalidixic acid 18 18 0
Rifampicin 39 42 0.16
Vancomycin 20 22 0.21
S.haemolyticus 41 Gentamycin 24 26 0.17
Ciprofloxacin 21 22 0.10
Methicillin No zone No zone 0
Nalidixic acid No zone No zone 0
Rifampicin 35 37 0.12
Vancomycin 20 20 0
In the absence of bacterial growth inhibition zones, the antibiotic disk diameter (6 mm) were used to calculate the
increase in fold area
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result provide an insight into the development of new antimi-
crobial formulations based on biosynthesized AuNPs with
potential inhibitory effect toward multidrug-resistant isolates
of coagulase-negative staphylococci.
Characterization of AuNPs functionalized with antibiotics
The formation of biosynthesized AuNPs functionalized with
four antibiotics, ciprofloxacin, gentamycin, rifampicin, and
vancomycin were monitored using UV–Vis spectroscopy
(Hitachi U5100). The SPR band typical of the gold nanopar-
ticles lies in the visible region of the electromagnetic spec-
trum, and it provides information regarding particle size dis-
tribution and aggregation [8]. The UV–Vis spectra of AuNPs
conjugated with four antibiotics (Fig. 5) showed no significant
change in the position of peak and color of the resulting solu-
tion even after conjugating with antibiotics. This indicates the
nonaggregated nature of conjugates formed and is in accor-
dance with previous report on functionalization of AuNPs with
streptomycin, neomycin, gentamycin, and kanamycin [13].
FTIR (Schimadzu IR Prestige 21) was used to investigate
the nature of binding of antibiotics to gold nanoparticles. The
IR spectra of free antibiotics and antibiotic-coated gold nano-
particles are shown in Fig. 6. All the antibiotics except rifam-
picin showed characteristic absorption band at 16,300–
1635 cm−1 corresponding to the N–H bending frequency
[13]. In the case of antibiotic-coated gold nanoparticles, N–
H bending peak was shifted to higher wavelength. Rifampicin
showed an absorption band at 2922 and 2939 cm−1 due to
symmetrical and asymmetrical stretching of methylene group
[15], and this band is shifted to 2949 in rifampicin–AuNPs
conjugate. In addition, N–H bending peak at 1645 cm−1 was
also observed in the IR spectrum of rifampicin-coated gold
nanoparticles. Based on the spectral data, binding of the amino
groups of antibiotics to the surface of gold nanoparticles could
be confirmed. Gold nanoparticles have strong affinity for
amine groups and a previous report on vancomycin-bound
biogenic AuNPs suggested the ability of gold nanoparticles
to react with vancomycin by ionic interaction between amino
group of antibiotic and negative surface charge of gold nano-
particles [10, 28].
Antibacterial activity of AuNPs functionalized antibiotics
The antibacterial activity of antibiotics and antibiotic-bound
biogenic gold nanoparticles were tested against CoNS strains
based on liquid broth dilutionmethod, andMICs of antibiotics
were analyzed (Table 2). It was found that MICs of all AuNP-
conjugated antibiotics reduced significantly compared to their
free forms except rifampicin-bound AuNPs against
S. epidermidis 152, and vancomycin-bound AuNPs against
S.haemolyticus 41. As CoNS have the ability to express resis-
tance to multiple antibiotics, treatment of CoNS infections is
complicated. Also, resistance to methicillin is almost universal
among CoNS, and so, vancomycin is usually the antibiotic of
choice for treatment. However, it has been reported that this
Fig. 5 The UV–Vis absorption
spectra of biogenic gold
nanoparticles functionalized with
antibiotics
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glycopeptide susceptibilities of clinically significant staphylo-
cocci are also decreasing. However, AuNP-bound vancomy-
cin was found to reduce theMIC of this antibiotic from 62.5 to
15.65 μg/ml against all tested S. epidermidis isolates. Similar
result was also observed with ciprofloxacin against
S. epidermidis 152 and S. haemolyticus 41. Both gentamycin
and rifampicin were less effective against S. epidermidis 152
compared to other antibiotics. Also, the antibacterial efficacy
of gentamycin is increased when bound with AuNPs and re-
duced its MIC from 125 to 31.25 μg/ml.
Antibacterial efficiency of AuNP-bound antibiotics has
already been reported and in the case of gentamycin, which
contains active groups that react with nanogold by chelation.
Gold nanoparticles possess a large surface to volume ratio and
because of this more number of drug molecules gets adsorbed
on its surface. When the antimicrobial groups come in close
proximity with a nanogold core it has been suggested to act
very effectively against the microorganisms [15]. Because of
this, vancomycin-capped AuNPs (Au@VanNPs) has reported
to have 64-fold improved efficacy against VRE strains and
E. coli than vancomycin alone [11]. A similar result has also
Table 2 Minimum inhibitory concentration (μg/ml) of antibiotics and
antibiotics bound gold nanoparticles against CoNS strains
Antibiotics CoNS isolates
73 152 78 41
A B A B A B A B
Ciprofloxacin 31.25 7.81 62.5 15.62 31.25 3.9 62.5 15.62
Gentamycin 31.25 3.9 125 31.25 31.25 15.62 31.25 7.81
Rifampicin 31.25 7.81 125 125 31.25 15.62 62.5 15.62
Vancomycin 62.5 15.65 62.5 15.62 62.5 15.62 62.5 62.5
Columns A and B represent the MIC values in μg/ml of antibiotics and
AuNPs functionalized antibiotics, respectively
Fig. 6 FTIR spectra of gold nanoparticles-antibiotics conjugates a AuNPs-ciprofloxacin, b AuNPs-gentamycin, c AuNPs-rifampicin, and d AuNPs-
vancomycin
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been reported for ciprofloxacin-coated AuNPs [28]. In addition,
the antibacterial mechanism of VBGNP against vancomycin-
resistant S. aureus (VRSA) was reported to be due to the non
specific binding of VBGNP to the transpeptidase instead to
terminal peptides (D Lac) of VRSA strain [10]. Thus, it can be
confirmed that gold nanoparticles act as a good anchor for car-
rying more amount of drugs effectively on its surface via elec-
trostatic attraction and which signifies application of AuNP-
based nanoconjugates for surface engineering applications.
The important advantages of nanoparticle-based antimicro-
bial drug delivery includes improved solubility of poorly water-
soluble drugs, prolonged drug half-life and systemic circulation
time, and sustained and stimuli-responsive drug release, which
eventually lowers administration frequency and dose [6, 29]. In
addition, minimized systemic side effects through targeted
delivery of antimicrobial drugs as well as combined, synergistic,
and resistance overcoming effects via co-delivery of multiple
antimicrobial drugs can also be achieved using nanoparticle car-
riers [30]. Because of the enhanced antibacterial effect of AuNP-
antibiotic conjugates, it can be used as potential template for the
designing of new biocompatible antibacterial agents to engineer
surface of medical devices to prevent bacterial colonization and
to overcome drug resistance. Thus, the antibacterial effect of
gold nanoparticles functionalizedwith antibiotics on the survival
of CoNS investigated in this study is very innovative and pro-
mising and the conjugates developed in the study can be of
immense application to modify the surface of medical device
or targeted delivery of antibiotics to CoNS to limit its infection.
Conclusion
In the present study, biosynthesis of highly stable AuNPs by
soilBacillus sp. and its antibacterial activity functionalized with
antibiotics were studied to combat multidrug-resistant bacteria.
AuNPs were functionalized with antibiotics ciprofloxacin,
gentamycin, rifampicin, and vancomycin and characterized
using UV–Vis spectroscopy and FTIR. Even though AuNPs
does not have any antibacterial activity, it was found to act as
carrier for drugs and the antibiotic-bound AuNPs showed very
effective activity against CoNS strains compared to pure drugs.
Thus, antibacterial effects of AuNP-antibiotic conjugate deve-
loped in the study shows biosynthesized AuNPs as an effective
drug delivery vehicle which is of much potential applications.
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